Mirati Therapeutics Inc
Mirati Therapeutics is a clinical-stage targeted oncology company. It develops novel therapeutics that target the genetic and immunological drivers of cancer and help extend the lives of cancer patients. Mirati is currently focused on developing a cancer therapeutic drug called sitravatinib, which is designed to selectively target a spectrum of tyrosine kinases implicated in both tumor growth and the suppression of immune responses to tumors. Sitravatinib is currently enrolling patients for Phase 3 trials.
The company reported its Q12020 earnings in early May of 2020. The company had reported a loss of $2.02 per share as compared to a loss of $1.17 per share during the same quarter the previous year.
Later in May of 2020, the company had announced the appointment of Joseph Leveque, M.D. as the company’s chief medical officer. Dr. Isan Chen, M.D., the incumbent chief medical officer stepped down but continued to act as an advisor to the company.
According to Dr. Charles Baum, CEO, Mirati Therapeutics, ” Joe’s experience with world-class clinical development teams that have brought several novel oncology therapies to patients will have an important impact as we prepare for Mirati’s next phase of growth.” He further added, ” We are thrilled to have him join Mirati as we rapidly advance our registration-enabling clinical trials for both sitravatinib and MRTX849, as well as advance our preclinical pipeline including the KRAS G12D inhibitor program.”
Mirati Therapeutics stock (Nasdaq:MRTX) closed at $117.38, up 12.45% for the past month.